FUJIFILM Diosynth Biotechnologies Launches First Phase of Global CDMO Ecosystem Expansion

HILLERØD, DENMARK, November 5, 2024 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, proudly announces that the first phase of its expansion at the Hillerød site is ready to bring the new production capacity into operation.

This milestone marks the initial step in the company’s strategy to build a comprehensive global ecosystem dedicated to enhancing the production and delivery of life-saving medicines.

This first phase adds six mammalian cell bioreactors, bringing the total capacity at the Hillerød site to 12 x 20,000 L bioreactors. A previously announced major capital investment will support the next phase, which will include an additional 8 x 20,000 L bioreactors and two downstream processing streams. By mid-2025, fill/finish production is scheduled to commence, with full expansion expected to be in operation by 2026, increasing the site footprint to approximately 51,500m² and creating up to 2,200 jobs.  

“Our operations in Hillerød represent our commitment to being the world-leading partner for life – supporting our customers and their patients globally,” said Christian Houborg, site head and senior vice president of FUJIFILM Diosynth Biotechnologies. “This expansion is a testament to our vision for introducing robust capabilities into the global biopharma landscape, ensuring the timely delivery of critical therapies to those in need.”

Since 2011, FUJIFILM Corporation has invested over $8 billion USD to establish a formidable global network for biologics manufacturing. This includes strategically located modular facilities designed to provide the agility needed for rapid production scaling. In 2025, operations will begin at the first phase of FUJIFILM Diosynth Biotechnologies’ large-scale facility in Holly Springs, North Carolina, further reinforcing the Company’s commitment to building its transformative ecosystem. 

“The Hillerød facility is the first expansion in our global network, which will include further developments in the US, UK, and Japan,” said Lars Petersen, president and chief executive officer, FUJIFILM Diosynth Biotechnologies. “By investing in state-of-the-art facilities on both sides of the Atlantic and prioritizing our workforce, we are uniquely positioned to meet the evolving needs of our partners and the patients they serve.”

This expansion also aligns with the Company’s sustainability initiative, Partners for the Planet, which incorporates sustainable practices across all facilities. The Hillerød site has signed a ten-year Power Purchase Agreement^*1 to source all electricity from renewable sources, contributing to its silver certification from the globally recognized EcoVadis standard.

“This is just the beginning. With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of the life-impacting medicines that make patients’ lives better,” Lars Petersen concluded.

• *1 A Power Purchase Agreement is a long term contract between a electricity generator (the seller) and an electricity consumer (the buyer, normally a corporate or a utility) for the production and offtake of electricity. The generator constructs, operates and maintains the physical energy asset and the customer consumes and pays for the electricity delivered. PPA’s are commonly used in relation to the construction of new renewable energy assets, which are often located outside the consumers premises and delivered via the public electricity grid.

• * Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.